BBIO vs EXEL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BBIO · BridgeBio Pharma$74.29 ▲ 0.03%
EXEL · Exelixis$69.57 ▲ 1.25%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BBIO +18.3%
- EXEL +68.0%
Head to head
| Metric | BBIO | EXEL |
|---|---|---|
| Price | $74.29 | $69.57 |
| Change today | ▲ 0.03% | ▲ 1.25% |
| Market cap | $14.47B | $16.98B |
| Return, 3 months | -12.3% | +31.4% |
| Return, year to date | -2.9% | +58.7% |
| Return, 1 year | +20.2% | +70.5% |
| P/E (TTM) | – | 20.8 |
| P/B | -5.6 | 9.3 |
| P/E percentile vs own 5y | 0th | 41st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +120.4% | +10.2% |
| Net profit growth (YoY) | +15.2% | +12.7% |
| Gross margin | 94.4% | 96.3% |
| Operating margin | -67.0% | 40.2% |
| Net margin | -97.0% | 35.5% |
| Return on equity | – | 44.3% |
| Analyst target vs. price | +47.7% | -6.6% |
| Analyst buy share | 94% | 57% |
| RSI (14) | 60 | 66 |
| 30-day volatility | 35.2% | 28.3% |
| Max drawdown, 1 year | -29.8% | -12.6% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- EXEL is the largest of the group by market value.
- EXEL has returned the most over the past year.
- BBIO is growing revenue fastest.
- EXEL keeps the most profit per dollar of sales.
- EXEL has been the calmest stock over the last 30 days.